Gainesville, GA – December 07, 2016 – It’s estimated that approximately 13 percent of DMD patients potentially may be eligible for treatment right away. This advancement is one of the outcomes Mansfield has been working towards with the Muscular Dystrophy Association over the last three decades.
“Mansfield is excited to be a part of the continuous progress MDA is making with its investment in research and clinical trials to help find cures for muscular diseases,” said Mansfield Oil Company President Blake Young. “The FDA’s approval of this treatment is a tremendous advancement,” he added.
This announcement is a huge step for MDA. It brings with it a renewed sense of urgency and purpose across the organization.
“We are honored to stand shoulder to shoulder with all of the Mansfield team members, both present and past, who have helped make the [DMD treatment approval] a reality,” said Meg Hodges, Chief Executive for MDA’s Southeastern States.
Mansfield is extremely appreciative of the many participants of the annual Mansfield Golf Classic for who have helped generate more than $5.9 million dollars we’ve contributed to MDA’s mission. We are all to be commended for supporting MDA in the fight against horrible muscle diseases, and the ongoing work to finding cures for all of them.
Proceeds from the Annual Mansfield Golf Classic are donated to MDA to fund research, clinical trials, support services, and independence programs for families affected by Muscular Dystrophy and related diseases. For more information about this event, visit www.mansfieldgolfclassic.com.